KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Depreciation & Amortization (CF) (2017 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed Depreciation & Amortization (CF) for 18 consecutive years, with $13.6 million as the latest value for Q1 2026.

  • For Q1 2026, Depreciation & Amortization (CF) fell 5.91% year-over-year to $13.6 million; the TTM value through Mar 2026 reached $54.8 million, down 4.78%, while the annual FY2025 figure was $55.7 million, 1.79% down from the prior year.
  • Depreciation & Amortization (CF) hit $13.6 million in Q1 2026 for Alnylam Pharmaceuticals, roughly flat from $13.5 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $15.0 million in Q2 2024 and bottomed at $9.5 million in Q1 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $13.2 million, with a median of $13.6 million recorded in 2026.
  • Year-over-year, Depreciation & Amortization (CF) dropped 24.93% in 2022 and then skyrocketed 48.68% in 2023.
  • Alnylam Pharmaceuticals' Depreciation & Amortization (CF) stood at $14.3 million in 2022, then dropped by 5.79% to $13.5 million in 2023, then grew by 5.09% to $14.2 million in 2024, then decreased by 4.67% to $13.5 million in 2025, then rose by 0.35% to $13.6 million in 2026.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $13.6 million, $13.5 million, and $13.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.